Veracyte Q4 revenue $140.6M (+19% YoY); GAAP net income $41.1M, generates $52.6M operating cash

VERACYTE, INC.

2025-FY EPS reported $0.82 revenue$517,145,000

Q4 total revenue $140.6M (+19% YoY); testing revenue $135.8M (+21%); total volume 48,019 tests (+16%).
Decipher revenue $85.6M (+27%); Afirma revenue $47.9M (+16%); strong double-digit growth in both segments.
GAAP net income $41.1M (29.3% margin); adjusted EBITDA $42.3M (30.1% margin); $52.6M operating cash flow.
Full-year 2025 revenue $517.1M (+16% YoY); GAAP net income $66.4M; adjusted EBITDA $142.5M; operating cash $136.3M.
Ended 2025 with $412.9M cash; plans to launch Prosigna LDT and TrueMRD test in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.